Mode
Text Size
Log in / Sign up
Phase 3 N=404 Randomized Double-blind Treatment

Clinical Trial in Females for Female Pattern Hair Loss

Androgenetic Alopecia

Enrolled (actual)
404
Serious AEs
2.5%
Results posted
Jun 2014
Primary outcome: Primary: Target Area Hair Count — 152.7; 158.6; 162.2; 175.7 hairs per centimeter squared — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
5% Minoxidil Topical Foam (Drug); Vehicle Topical Foam (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Primary completion
Aug 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Target Area Hair Count
152.7; 158.6; 163.3; 178.1; 5.4; 16.4 <0.0001 sig
PRIMARY
Subject Assessment of Scalp Coverage
0.06; 0.74 <0.0001 sig
SECONDARY
Target Area Hair Count
152.7; 158.6; 163.3; 178.1; 5.4; 16.4 <0.0001 sig

Summary

This is a six month clinical trial to evaluate the effectiveness and safety in women with Female Pattern Hair Loss (FPHL), comparing a 5% minoxidil topical foam (MTF) formulation applied once a day versus a topical foam vehicle (placebo) formulation applied once a day.

Eligibility Criteria

Inclusion Criteria

  • females, age 18 or older in general good health
  • exhibits female pattern hair loss
  • signs and dates an informed consent document
  • agrees to use an adequate method of birth control; if of childbearing potential
  • shows a negative urine pregnancy test at Screening Visit
  • is willing to maintain the same hair style, hair color, and hair regimen throughout the study
  • is willing and able to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures

Exclusion Criteria

  • hypersensitivity to the (study product), or any ingredients of the (study product)
  • known allergy to hair dye, or hair dye components
  • clinically relevant history of hypotension
  • untreated or uncontrolled hypertension
  • pregnant, planning a pregnancy or nursing a child
  • history of hair transplants
  • currently use hair weaves or non-breathable wigs
  • dermatologic disorders of the scalp that require chronic use of medication for control
  • other types or history of hair loss
  • enrolled in any other investigational medication (drug) study currently, or within the last 6 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01226459). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search